Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02031419 · ClinicalTrials.gov registry record · Phase 1
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
NCT02031419 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 174 participants.
The verdict
NCT02031419, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
Study Summary
First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma
Interventions
- DRUG Rituximab
- DRUG CC-122
- DRUG CC-292
- DRUG CC-223
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2013-12-18 |
| Est. Completion | 2023-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02031419
The ClinicalTrials.gov registry entry for NCT02031419 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rituximab is the first listed.
NCT02031419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02031419 about?
NCT02031419 is a clinical study titled "Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma". First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma
What is the current status of trial NCT02031419?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2013-12-18. Estimated completion is 2023-12-12.
What interventions are being tested in trial NCT02031419?
The interventions under investigation include: Rituximab (DRUG), CC-122 (DRUG), CC-292 (DRUG), CC-223 (DRUG).
Who is sponsoring clinical trial NCT02031419?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.